Key messages[1]:
• 32 IdyllaTM commercial instruments sold in H1 2015. Guidance of 75 instruments sold in 2015 reiterated. • Continued strong ramp up of global sales and distribution network, now covering 50 countries and nine new distribution contracts signed in H1 2015.
• Significant progress in test menu development:
• CE-IVD mark for KRAS Mutation Test for colorectal cancer received in June 2015; and
• Three new collaborations signed with development partners for further menu expansion in both oncology and infectious diseases.
• Menu outlook H2 2015:
• Acceleration in market launch of IFV-RSV test to Q4 2015;
• NRAS Research Use Only (RUO) Mutation Test launch expected in Q4 2015 (CE-IVD launch expected in H1 2016); and
• Completion of EUA submission Rapid Ebola Virus Triage Test expected in Q4 2015.
• Solid cash position of EUR 128m at end of H1 2015, primarily driven by successful EUR 115m IPO in April 2015.
• Strengthening of management team with appointment of Hilde Windels as Deputy CEO and Ewoud Welten as CFO. Rudi Pauwels will continue to lead the Company as CEO.
Biocartis will host a webcast presentation today at 14:00 CET to discuss the H1 2015 results and the strengthening of its management team. To access the live webcast, please visit Biocartis’ website at https://investors.biocartis.com or by clicking here at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. The webcast presentation is also made available at https://investors.biocartis.com.
Mechelen, Belgium, 11 September 2015: Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announced its operational highlights and financial results for the first half of 2015, prepared in accordance with the IAS 34 ‘Interim Financial Reporting’ as adopted by the European Union. Furthermore, the Company is pleased to announce that is has strengthened its management team.
For more information, please contact:
Biocartis
Renate Degrave (Corporate Communications & Investor Relations)
+32 15 632 600
press@biocartis.com
Consilium Strategic Communications
Amber Fennell, Jessica Hodgson, Chris Welsh, Hendrik Thys
+44 (0) 203 709 5701 (Londen, VK)
biocartis@consilium-comms.com
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis’ proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.
Biocartis launched the Idylla™ platform commercially in September 2014 together with its first assay to identify BRAF Mutations in metastatic melanoma. Its second assay, a KRAS Mutation panel for colorectal cancer has been launched in June 2015. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Further information can be found at: www.biocartis.com
Help employers find you! Check out all the jobs and post your resume.
